British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted to the second half of the year, overshadowing a strong end to 2024 and sending its shares down by more than 3%.

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Sensodyne-maker Haleon’s annual profits rose in line with expectations last year as it got a boost in demand for its oral hygeine and multi-vitamin products. The business, spun off from drugmaker GSK in 2022, saw operating profit rise 10.5% to £2.5bn in the year to 31 December, matching analysts’ expectation.

UK's Haleon reported annual profit in line with market expectations on Thursday, as the Sensodyne toothpaste and Advil painkiller maker was helped by sustained demand for its multi-vitamin and oral health products.

The maker of Panadol, Sensodyne toothpaste and Centrum vitamins posted a higher pretax profit for 2024 despite lower revenue.